Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by TD Asset Management Inc

Key Points

• TD Asset Management Inc has reduced its stake in Regeneron Pharmaceuticals by 8.2%, now owning about 0.30% of the company after selling 29,030 shares.
• Regeneron Pharmaceuticals reported $12.89 EPS for its last quarter, exceeding analysts' expectations of $8.43, and its revenue increased 3.6% year-over-year to $3.68 billion.
• After recent adjustments, the consensus rating for Regeneron Pharmaceuticals is a "Moderate Buy," with a consensus price target of $817.88.

TD Asset Management Inc decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 8.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 322,857 shares of the biopharmaceutical company's stock after selling 29,030 shares during the quarter. TD Asset Management Inc owned about 0.30% of Regeneron Pharmaceuticals worth $169,500,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Kingswood Wealth Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 1.8% during the first quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock worth $681,000 after acquiring an additional 19 shares during the period. Creative Financial Designs Inc. ADV grew its holdings in Regeneron Pharmaceuticals by 9.5% during the first quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock worth $139,000 after acquiring an additional 19 shares during the period. Private Trust Co. NA grew its holdings in Regeneron Pharmaceuticals by 13.1% during the first quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company's stock worth $104,000 after acquiring an additional 19 shares during the period. Proficio Capital Partners LLC grew its holdings in Regeneron Pharmaceuticals by 6.2% during the first quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company's stock worth $207,000 after acquiring an additional 19 shares during the period. Finally, Cove Private Wealth LLC grew its holdings in Regeneron Pharmaceuticals by 4.5% during the first quarter. Cove Private Wealth LLC now owns 460 shares of the biopharmaceutical company's stock worth $292,000 after acquiring an additional 20 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on REGN shares. Morgan Stanley lowered their target price on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an "overweight" rating on the stock in a report on Friday, October 10th. Raymond James Financial raised Regeneron Pharmaceuticals to a "moderate buy" rating in a report on Tuesday, September 2nd. Truist Financial dropped their price target on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. Wells Fargo & Company cut Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price target on the stock. in a research note on Friday, August 1st. Finally, Jefferies Financial Group lifted their price target on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a research note on Wednesday, August 27th. Three analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $817.88.

Regeneron Pharmaceuticals Trading Up 2.7%

Shares of NASDAQ REGN opened at $572.60 on Wednesday. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,024.36. The firm has a market capitalization of $60.69 billion, a PE ratio of 14.43, a PEG ratio of 1.78 and a beta of 0.31. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The business has a 50-day moving average price of $573.72 and a two-hundred day moving average price of $563.52.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. During the same period last year, the company posted $11.56 EPS. The business's quarterly revenue was up 3.6% compared to the same quarter last year. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.